Get the Stockscreener App
60.78
1.15%
0.69
After Hours:
61.11
0.33
+0.54%
Disc Medicine Inc stock is traded at $60.78, with a volume of 595.69K.
It is up +1.15% in the last 24 hours and down -8.77% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$60.09
Open:
$59.37
24h Volume:
595.69K
Relative Volume:
0.89
Market Cap:
$2.32B
Revenue:
-
Net Income/Loss:
$-212.18M
P/E Ratio:
-10.15
EPS:
-5.9897
Net Cash Flow:
$-181.33M
1W Performance:
+2.83%
1M Performance:
-8.77%
6M Performance:
-8.02%
1Y Performance:
+16.08%
1-Day Range:
$58.35
$62.11
1-Week Range:
$58.15
$63.27
52-Week Range:
$30.82
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
60.78 | 2.29B | 0 | -212.18M | -181.33M | -5.9897 |
VRTX
Vertex Pharmaceuticals Inc
|
443.16 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.29 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
704.31 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.09 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
153.32 | 31.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Stifel reiterates Disc Medicine stock rating after rival drug data - Investing.com
Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Investors to Connect - ACCESS Newswire
Expanded Phase 3 APOLLO Enrollment for Bitopertin in EPP/XLP Might Change The Case For Investing In Disc Medicine (IRON) - Sahm
Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ... - Bluefield Daily Telegraph
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
2026-03-27 | Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Stockholders to Inquire about Securities Investigation | NDAQ:IRON | Press Release - Stockhouse
Disc Medicine, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
A Look At Disc Medicine (IRON) Valuation As APOLLO Phase 3 Trial Reaches Full Enrollment Milestone - Sahm
Disc Medicine completes enrollment in bitopertin EPP trial By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Published on: 2026-03-27 10:30:49 - baoquankhu1.vn
Disc Medicine completes enrollment in bitopertin EPP trial - Investing.com
Disc Medicine announces completion of enrollment of phase 3 Apollo trial of bitopertin in erythropoietic protoporphyria - marketscreener.com
Disc Medicine Announces Completion Of Enrollment Of Phase 3 Apollo Trial Of Bitopertin In Erythropoietic Protoporphyria - TradingView
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria - The Manila Times
Disc Medicine Announces Completion of Enrollment of Phase 3 Apollo Trial of Bitopertin in Erythropoietic Protoporphyria - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.IRON - PR Newswire
Assenagon Asset Management S.A. Grows Position in Disc Medicine, Inc. $IRON - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Stockholders to Connect - ACCESS Newswire
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IRON Investors Lose Up to $22/Share -- LEVI & KORSINSKY, LLP Investigates Disc Medicine - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRON - ChartMill
Update Report: Will Disc Medicine Inc outperform during market ralliesGold Moves & Community Consensus Picks - baoquankhu1.vn
IRON Investor News: If You Have Suffered Losses in Disc - GlobeNewswire
Growth Review: Will Disc Medicine Inc outperform during market rallies2026 Technical Overview & Fast Gain Stock Trading Tips - baoquankhu1.vn
JPMorgan Chase & Co. Sells 90,737 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Hudson Bay Capital Management LP Acquires Shares of 102,185 Disc Medicine, Inc. $IRON - MarketBeat
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - chartmill.com
Disc Medicine targets dermatology growth with new bitopertin update at AAD conference - Traders Union
Disc Medicine announces public offering of common stock and pre-funded warrants - MSN
Trade Recap: Is Disc Medicine Inc stock trending bullishDip Buying & Weekly Top Performers Watchlists - baoquankhu1.vn
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation – IRON - The Joplin Globe
IRON Drops Up to 39% After FDA CRL for Bitopertin -- LEVI & KORSINSKY, LLP Investigates - GlobeNewswire
Disc Medicine, Inc. (IRON) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - The Globe and Mail
IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
First Light Asset Management LLC Acquires New Holdings in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine, Inc. (NASDAQ:IRON) Sees Large Growth in Short Interest - MarketBeat
Checkpoint Capital L.P. Acquires 165,000 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Atlas Venture Life Science Advisors LLC Has $141.58 Million Stock Position in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine, Inc. $IRON Stake Trimmed by Victory Capital Management Inc. - MarketBeat
Is Disc Medicine (IRON) Pricing Attractive After Recent Pullback And DCF Valuation Gap - simplywall.st
IRON Investors Lose Up to $22/Share — LEVI & KORSINSKY, LLP Investigates Disc Medicine - Morningstar
Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation Signals - Yahoo Finance
IRON: Phase III data for bitopertin and key pipeline readouts are expected by year-end - TradingView
Disc Medicine (IRON) Is Down 8.2% After Wider 2025 Loss and ESOP Shelf FilingHas The Bull Case Changed? - simplywall.st
Disc Medicine Stock Pre-Market (+9.8%): Sector Lift on J&J Hematology Approval - Trefis
Blue Owl Capital Holdings LP Sells 20,000 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):